| Similar Articles |
|---|
 |
American Journal of Nursing
June 2011
Karen Roush |
Menopausal Hormone Therapy: What We Know Now This article describes the findings and limitations of the major research thus far on hormone therapy.   |
American Family Physician
March 15, 2004 |
Breast Cancer Risk Related to Type of Hormone Therapy Although several studies have demonstrated an increased risk of breast cancer in postmenopausal women taking oral hormone therapy, the risk related to each of the various forms of therapy is less clear. |
American Family Physician
December 15, 2005
Janelle Guirguis-Blake |
Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women The case study and answers to the following questions on hormone therapy for the prevention of chronic conditions in postmenopausal women are based on the recommendations of the U.S. Preventive Services Task Force (USPSTF). |
Nurse Practitioner
July 2011
Kass-Wolff & Fisher |
Menopause and the Hormone Controversy: Clarification or Confusion? Hormone therapy in perimenopause and menopause remains a controversial and often confusing management strategy for healthcare providers. To assist in providing women quality healthcare, recently published new guidelines help provide direction for NPs. |
American Family Physician
February 15, 2005
Mark H. Ebell |
Evidence-Based Initiation of Warfarin (Coumadin) Many physicians continue to use clinical judgment alone as the basis for initiating and adjusting warfarin dosages in patients who require oral anticoagulation. |
American Family Physician
June 15, 2004
Ramzi & Leeper |
DVT and Pulmonary Embolism: Part II. Treatment and Prevention Evaluation for thrombophilias and other secondary causes of venous thromboembolic disease, presents an evidence-based approach to the treatment of DVT and PE, and reviews current recommendations for prevention of venous thromboembolism. |
Salon.com
July 10, 2002
Trisha Posner |
Death by hormones It's been more than 50 years since studies first sounded the alarm about hormone replacement therapy. Women, silenced by shame, have been guinea pigs of the pharmaceutical industry for too long. |
American Family Physician
March 15, 2004 |
Use of Ultra-Low-Dose Estrogen to Prevent Bone Loss Estrogen therapy recently has been shown to increase the risk of breast cancer, heart disease, stroke, and deep venous thrombosis, but it also decreases the risk of hip fracture. |
American Family Physician
March 15, 2001
Jeannette E. South-Paul |
Osteoporosis: Part II. Nonpharmacologic and Pharmacologic Treatment Family physicians will frequently encounter patients with osteoporosis, a condition that is often asymptomatic until a fracture occurs... |
American Journal of Nursing
June 2009
Stein & Henry |
Poor Oral Hygiene in Long-Term Care The poor oral care given to vulnerable patients in long-term care settings can have serious consequences, including increased risk of stroke, heart disease, and pneumonia. |
The Motley Fool
December 27, 2006
Brian Lawler |
Bradley's Mediocre Drug Approval With the FDA's approval of Bradley's Elestrin, shares were up over 10% upon approval last week. |
Nurse Practitioner
January 2011
Reimer & Johnson |
Atrophic vaginitis signs, symptoms, and better outcomes This article reviews physiology, clinical manifestations, signs, symptoms, and treatment methods for atrophic vaginitis. |
The Motley Fool
September 17, 2007
Brian Orelli |
Preventing Cancer, No Bones About It For Eli Lilly, the only thing better than having a drug with more than $1 billion in annual sales is getting it approved to treat more patients. That's what just happened with their cancer drug, EVISTA. Investors, take note. |
The Motley Fool
November 22, 2010
Brian Orelli |
Pfizer's Mixed Bag Pfizer had a mixed bag of clinical trial results at the end of last week. And probably the company would have rather seen the results flip-flopped. |
American Family Physician
December 15, 2004
Pamela Dull |
STEPS The transdermal patch of oxybutynin is no more effective than the short- or long-acting oral form. The patch costs more, but causes less dry mouth. Skin reactions will cause about 10 percent of patients to stop using it. |
